title: Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis.
abstract: BACKGROUND
  The optimal ovarian stimulation dose to obtain the best balance between the probability of pregnancy and the risk of complications, while maximizing cost-effectiveness of in vitro fertilization (IVF) treatment, is yet to be established.
  
  
  METHODS
  A systematic search of the electronic databases PubMed, EMBASE and Cochrane library, from 1984 until October 2009 for randomized controlled trials comparing different doses of recombinant FSH in IVF, was performed.
  
  
  RESULTS
  Ten studies (totaling 1952 IVF cycles) were included in the present meta-analysis, comprising patients younger than 39 years with regular menstrual cycle, normal basal FSH levels and two normal ovaries. Comparison was made between studies using a daily dose of 100 versus 200 IU recFSH, and between 150 versus 200 IU recFSH or higher. Although oocyte yield was greater in the >200 IU/day dose group, pregnancy rates were similar compared with lower dose groups. The risk of insufficient response to ovarian stimulation was greatest in the 100 IU/day dose group. The risk of developing ovarian hyperstimulation syndrome was greater in the >200 IU/day dose group. The number of embryos available for cryopreservation was lowest in the 100 IU/day group, but similar comparing the 150 IU/day and the >200 IU/day dose groups.
  
  
  CONCLUSIONS
  This meta-analysis suggests that the optimal daily recFSH stimulation dose is 150 IU/day in presumed normal responders younger than 39 years undergoing IVF. Compared with higher doses, this dose is associated with a slightly lower oocyte yield, but similar pregnancy and embryo cryopreservation rates. Furthermore, the wide spread adherence to this optimal dose will allow for a considerable reduction in IVF costs and complications.
authors.affiliation: Department of Reproductive Medicine and Gynaecology, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht, The Netherlands. m.d.sterrenburg@umcutrecht.nl
authors.forename: M D
authors.initials: MD
authors.lastname: Sterrenburg
authors.forename: S M
authors.initials: SM
authors.lastname: Veltman-Verhulst
authors.forename: M J C
authors.initials: MJ
authors.lastname: Eijkemans
authors.forename: E G
authors.initials: EG
authors.lastname: Hughes
authors.forename: N S
authors.initials: NS
authors.lastname: Macklon
authors.forename: F J
authors.initials: FJ
authors.lastname: Broekmans
authors.forename: B C J M
authors.initials: BC
authors.lastname: Fauser
mesh_terms: D000328:Adult; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D011994:Recombinant Proteins; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone